Home » Stocks » OCUP

Ocuphire Pharma, Inc. (OCUP)

Stock Price: $12.18 USD 0.45 (3.84%)
Updated Jan 26, 2021 4:00 PM EST - Market closed
Market Cap 130.37M
Revenue (ttm) 1.15M
Net Income (ttm) -6.37M
Shares Out 1.06M
EPS (ttm) -6.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $12.18
Previous Close $11.73
Change ($) 0.45
Change (%) 3.84%
Day's Open 11.76
Day's Range 11.51 - 12.20
Day's Volume 129,840
52-Week Range 1.31 - 12.20

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 6 days ago

Durability of Nyxol's Pupil Constricting Effects Using an Evening Dosing Regimen Informs Dosing Strategy for Phase 2 Trial in Presbyopia and Phase 3 Trial in NVD

GlobeNewsWire - 3 weeks ago

FARMINGTON HILLS, Mich., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for ...

GlobeNewsWire - 2 months ago

ROCKVILLE, Md., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) (“Rexahn”) announced today that the merger transaction between Rexahn and Ocuphire Pharma, Inc. is ...

GlobeNewsWire - 2 months ago

ROCKVILLE, Md., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) (“Rexahn”) announced today that at its special meeting of stockholders held on November 2, 2020, Re...

PRNewsWire - 6 months ago

NEW YORK, June 29, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger between Rexahn Pharmaceuticals, Inc. (NASDAQ: REXN) and Ocuphir...

Newsfile Corp - 7 months ago

New York, New York--(Newsfile Corp. - June 22, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Rexahn Pharmaceuticals, Inc. (...

GlobeNewsWire - 7 months ago

Transaction to Create a Nasdaq-listed Biopharmaceutical Company Focused on Advancing Ocuphire’s Late-Stage Clinical Pipeline of Ophthalmic Drug Candidates

About OCUP

Ocuphire Pharma, a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing various therapies for the treatment of various eye disorders. The company's pipeline includes small-molecule product candidates for front and back of the eye indications. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate to reduce pupil size that is entering into Phase 3 clinical development for dim light or night vision disturbances, and reversal pharmacologi... [Read more...]

Industry
Biotechnology
CEO
Douglas Swirsky
Country
United States
Stock Exchange
NASDAQ
Ticker Symbol
OCUP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for OCUP is 15.00, which is an increase of 23.15% from the latest price.

Price Target
$15.00
(23.15% upside)